Literature DB >> 21217486

Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1:2.

Ross Davenport1, Nicola Curry, Joanna Manson, Henry De'Ath, Amy Coates, Claire Rourke, Rupert Pearse, Simon Stanworth, Karim Brohi.   

Abstract

BACKGROUND: Damage control resuscitation targets acute traumatic coagulopathy with the early administration of high-dose fresh frozen plasma (FFP). FFP is administered empirically and as a ratio with the number of packed red blood cells (PRBC). There is controversy over the optimal FFP:PRBC ratio with respect to outcomes, and their hemostatic effects have not been studied. We report preliminary findings on the effects of different FFP:PRBC ratios on coagulation.
METHODS: This is a prospective observational cohort study of trauma patients requiring >4 U of PRBCs. Blood was drawn before and after each 4-U PRBC interval for prothrombin time and analysis by rotational thromboelastometry. Interval change in coagulation parameters were compared with the FFP:PRBC ratio received during each interval.
RESULTS: Sixty 4-U PRBC intervals from 50 patients were available for analysis. All measures of coagulation deteriorated with low FFP:PRBC ratios (<1:2). Maximal hemostatic effect was observed in the 1:2 to 3:4 group: 12% decrease in prothrombin time (p=0.006), 56% decrease in clotting time (p=0.047), and 38% increase in maximum clot firmness (p=0.024). Transfusion with ≥1:1 ratio did not confer any additional improvement. There was a marked variability in response to FFP, and hemostatic function deteriorated in some patients exposed to 1:1 ratios. The beneficial effects of plasma were confined to patients with coagulopathy.
CONCLUSIONS: Interim results from this prospective study suggest that FFP:PRBC ratios of ≥1:1 do not confer any additional advantage over ratios of 1:2 to 3:4. Hemostatic benefits of plasma therapy are limited to patients with coagulopathy.

Entities:  

Mesh:

Year:  2011        PMID: 21217486     DOI: 10.1097/TA.0b013e318202e486

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  31 in total

1.  Infrastructure and clinical practice for the detection and management of trauma-associated haemorrhage and coagulopathy.

Authors:  A Driessen; N Schäfer; V Albrecht; M Schenk; M Fröhlich; E K Stürmer; M Maegele
Journal:  Eur J Trauma Emerg Surg       Date:  2014-10-25       Impact factor: 3.693

2.  Combat: Initial Experience with a Randomized Clinical Trial of Plasma-Based Resuscitation in the Field for Traumatic Hemorrhagic Shock.

Authors:  Michael P Chapman; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; James Chandler; John Stringham; Eduardo Gonzalez; Hunter B Moore; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

3.  Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays.

Authors:  Eduardo Gonzalez; Ernest E Moore; Hunter B Moore; Michael P Chapman; Theresa L Chin; Arsen Ghasabyan; Max V Wohlauer; Carlton C Barnett; Denis D Bensard; Walter L Biffl; Clay C Burlew; Jeffrey L Johnson; Fredric M Pieracci; Gregory J Jurkovich; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

4.  Implementation of a military-derived damage-control resuscitation strategy in a civilian trauma center decreases acute hypoxia in massively transfused patients.

Authors:  Eric M Campion; Timothy A Pritts; Warren C Dorlac; Anjelica Q Nguyen; Sara M Fraley; Dennis Hanseman; Bryce R H Robinson
Journal:  J Trauma Acute Care Surg       Date:  2013-08       Impact factor: 3.313

5.  Plasma first in the field for postinjury hemorrhagic shock.

Authors:  Ernest E Moore; Theresa L Chin; Michael C Chapman; Eduardo Gonzalez; Hunter B Moore; Christopher C Silliman; Kirk C Hansen; Angela Sauaia; Anirban Banerjee
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

6.  Efficacy of a high FFP:PRBC transfusion ratio on the survival of severely injured patients: a retrospective study in a single tertiary emergency center in Japan.

Authors:  Daisuke Kudo; Junichi Sasaki; Satoshi Akaishi; Satoshi Yamanouchi; Tomoaki Koakutsu; Tomoyuki Endo; Takeaki Sato; Ryosuke Nomura; Hironao Yuzawa; Michio Kobayashi; Yotaro Shinozawa; Shigeki Kushimoto
Journal:  Surg Today       Date:  2013-02-19       Impact factor: 2.549

Review 7.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

8.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

9.  The survival impact of plasma to red blood cell ratio in massively transfused non-trauma patients.

Authors:  P G Teixeira; K Inaba; E Karamanos; P Rhee; I Shulman; D Skiada; K Chouliaras; D Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2016-04-27       Impact factor: 3.693

10.  Damage control resuscitation using blood component therapy in standard doses has a limited effect on coagulopathy during trauma hemorrhage.

Authors:  Sirat Khan; Ross Davenport; Imran Raza; Simon Glasgow; Henry D De'Ath; Pär I Johansson; Nicola Curry; Simon Stanworth; Christine Gaarder; Karim Brohi
Journal:  Intensive Care Med       Date:  2014-12-02       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.